Skip to content Skip to left sidebar Skip to right sidebar Skip to footer

Tag: #GlobalCapabilityCentre

Sanofi Expands Hyderabad GCC, Adds Nearly 2,000 Jobs in India

French pharmaceutical giant Sanofi is deepening its commitment to India with a major expansion of its Global Capability Centre (GCC) in Hyderabad. The company plans to add nearly 2,000 new jobs, increasing total headcount at the centre from over 2,600 employees to more than 4,500 professionals.

The expansion reflects Sanofi’s long-term strategy to strengthen its global operations by leveraging India’s growing pool of high-skilled talent in research, technology, and digital innovation.

Significant Investment to Support Growth

The expansion will be backed by a multi-hundred-million-dollar investment, though the company has not specified an exact hiring timeline. This move builds on Sanofi’s 2024 commitment to invest €400 million (approximately $474.6 million) in its India GCC operations by the end of the decade.

The investment signals a shift toward scaling high-value functions in India, positioning the Hyderabad centre as a critical part of Sanofi’s global ecosystem.

Focus on Innovation and Advanced Capabilities

The additional roles will span across several strategic domains, including:

  • Research & Development (R&D)
  • Artificial Intelligence (AI)
  • Data Innovation and Analytics
  • Medical Affairs
  • Commercial Capabilities
  • Corporate Functions

This indicates that Sanofi’s Hyderabad centre is evolving beyond traditional support services into a global innovation hub that contributes directly to enterprise-wide strategy and transformation.

India’s Growing GCC Ecosystem

Sanofi’s expansion comes at a time when India’s Global Capability Centre ecosystem is witnessing rapid growth. According to Anarock:

  • India hosts more than 1,700 GCCs
  • These centres employ over 1.9 million professionals
  • The GCC market could grow to $105–110 billion by 2030
  • The number of centres may exceed 2,400 by the end of the decade

What were once considered cost-efficient back-office operations have now transformed into innovation-led centres driving digital transformation, R&D, finance, and global operations.

Hyderabad: A Strategic Pharma Hub

Hyderabad has increasingly become a focal point for global life sciences and technology companies. The announcement precedes the city’s flagship biotechnology conference, BioAsia, where global pharmaceutical leaders such as Eli Lilly, Novo Nordisk, Merck, and Sanofi are expected to discuss research expansion and India’s pharmaceutical growth trajectory.

The timing further underscores Hyderabad’s growing importance in global healthcare innovation.

A Strategic Shift in Global Operations

For Sanofi, the Hyderabad GCC is emerging as a cornerstone of its global strategy. As pharmaceutical companies rebalance supply chains and invest heavily in digital capabilities, India’s skilled workforce and strong ecosystem make it a preferred destination for long-term investment.

This expansion not only strengthens Sanofi’s operational capabilities but also reinforces India’s position as a global hub for advanced research, AI, and pharmaceutical innovation.

Eli Lilly Expands in India: CEO Invites Job Seekers for Hyderabad Tech Hub

Global pharmaceutical giant Eli Lilly is strengthening its presence in India with a brand-new technology center in Hyderabad. Expected to be operational by mid-2025, the Hyderabad hub will be the company’s second capability center in the country, following the successful launch of its Bengaluru hub in 2016.

Hiring in Full Swing for Hyderabad Tech Hub

Eli Lilly’s CEO, David Ricks, recently spoke to CNBC-TV18, confirming that recruitment is already underway for the Lilly Capability Center India (LCCI) in Hyderabad. “We also have a tech hub in Bengaluru, but we’re expanding that in Hyderabad with a new tech center. We’re out hiring now,” Ricks stated, encouraging skilled professionals—especially technology engineers and data scientists—to apply.

In January, Eli Lilly announced its ambitious hiring plans, aiming to recruit between 1,000 and 1,500 professionals. India has been a key player in the company’s global research and development (R&D) operations, particularly through its Bengaluru center, which operates on a “follow the sun” model. This approach allows Indian teams to seamlessly take over projects from their US counterparts overnight, ensuring continuous progress in research and accelerating drug development.

Manufacturing Plans for Blockbuster Drug Mounjaro?

Beyond technology and R&D, speculation is growing about Eli Lilly’s manufacturing plans for its highly sought-after diabetes and weight-loss drug, Mounjaro (tirzepatide). When asked about the possibility of local production, Ricks remained open to the idea. “There’s a lot of discussion about localizing or regionalizing supply chains, and as India grows as a market for us—Mounjaro may change that. We’re open-minded about possibilities here,” he said.

Eli Lilly officially launched Mounjaro in India on March 21, after its initial introduction in the US in December 2023. The drug, already available in the UK and Europe under the same name, is marketed as Zepbound in the US for obesity treatment. Touted as a game-changer in the fight against diabetes and obesity, Mounjaro’s entry into the Indian market could significantly impact healthcare accessibility and treatment options.

Opportunities Await in Hyderabad

With Eli Lilly’s Hyderabad tech hub on track for a mid-2025 launch and hiring in full swing, this is an exciting time for job seekers in the tech and pharma sectors. The company’s investment in India highlights its commitment to innovation, global collaboration, and cutting-edge research.

Global

Syneriq Global Launches AI-First Global Capability Centre in Hyderabad

Hyderabad, March 12 — Syneriq Global has inaugurated its AI-First Global Capability Centre (GCC) in Hyderabad, marking a significant milestone in the city’s evolution as a hub for AI-driven innovation. Telangana IT Minister D. Sridhar Babu lauded the initiative, emphasizing its role in propelling Hyderabad towards becoming a global leader in AI product development.

“Artificial Intelligence is embedding itself deeply in every industry and aspect of life. Hyderabad has the talent, and we must transition from merely coding to developing and exporting AI products worldwide. The city should establish itself as a Global Value Centre,” Sridhar Babu stated at the launch event.

The ₹50-crore investment in the new GCC will accelerate Syneriq Global’s expansion, with plans to double its workforce to 1,500 employees and target $150 million in revenue. The 40,000-square-foot facility will serve as an AI innovation hub, focusing on product engineering, research, and incubation for AI-driven startups.

Syneriq Global’s founder, Sudhakar Pennam, highlighted the company’s AI-powered platforms, including Zyrix, KITAP, and DQ Gateway, which were developed at its Hyderabad innovation lab. The facility aims to foster cutting-edge advancements in AI and deep-tech solutions.

Telangana has witnessed a surge in Global Capability Centres across various industries, a trend actively supported by the state government. Sridhar Babu noted that Hyderabad already hosts over 300 GCCs, collectively employing more than two lakh professionals.

Madan Mohan Rao, MLA from Nizamabad, emphasized Hyderabad’s growing prominence in AI and deep-tech sectors, predicting a strong economic future for the city. “GCCs like this are setting the stage for Hyderabad to surpass other major tech cities. The state government is proactively securing investments and strengthening infrastructure to support this transformation,” he added.

As part of broader AI-focused initiatives, Telangana is planning a 200-acre AI city, further reinforcing Hyderabad’s reputation as a global technology powerhouse.

Source:deccanchronicle